Infectious diseases
What is RSV?
Learn more about respiratory syncytial virus (RSV)
What is RSV?
Our strategy
We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.
Our R&D focus is on four therapeutic areas: infectious diseases, HIV, immunology/respiratory and oncology
Infectious diseases
1 in 3
of us will be affected by shingles in our lifetime
Immunology/Respiratory
25yrs
of leading research to help people with inflammatory conditions
Oncology
~10m
people died from cancer in 2020, making it a leading cause of death worldwide
Behind the science
Discover how we're getting ahead

‘The roar I hear is the next stage of the rocket firing’: MAPS technology and the new age of vaccine development

Fresh insights could finally help us tackle RSV

‘I had never experienced anything like it’: the pain, risks, and first symptoms of shingles every adult should know

Age-related decline in immunity: why does it matter and what can be done about it?

‘We’re not a world of men – it's as simple as that’: how gender diversity in clinical trials improves health outcomes for women

AI and ML power better predictions for patient impact

Digital twin: using advanced technology to accelerate vaccine development

The ‘tripledemic’ will hit older people hard this winter – but there are things we can all do to reduce the impact
Outstanding people

INNOVATING TOGETHER 2021
Meet Kumaran: using mRNA technology to develop vaccines

INNOVATING TOGETHER 2022
Meet Meg: collaborating to do more

INNOVATING TOGETHER 2022
Meet Katie: using big data to help more patients

INNOVATING TOGETHER 2022
Meet Nancy: igniting change & innovation for patients living with Respiratory Syncytial Virus (RSV)

INNOVATING TOGETHER 2022
Meet Pal: combining the power of genetics and genomics

MY GSK STORY
Meet Doug: using data to inform GSKs decisions